Telix Pharmaceuticals (TLX) Receivables - Net (2023 - 2025)

Telix Pharmaceuticals (TLX) has reported Receivables - Net for 3 consecutive years, with $129.2 million the latest figure, recorded in Q4 2025.

• Quarterly Receivables - Net rose 31.2% year-over-year to $129.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $129.2 million (up 31.2% YoY) and the FY2025 annual result came in at $129.2 million, up 48.63% from the prior year.
• Receivables - Net rose to $129.2 million in Q4 2025 per TLX's latest filing, from $98.5 million in the prior quarter.
• Over the last five years, Receivables - Net for TLX reached as high as $129.2 million in Q4 2025 and fell as low as $46.1 million in Q4 2023.
• A 3-year average of $91.3 million and a median of $98.5 million in 2024 frame the typical range for Receivables - Net.
• Annual changes were most pronounced in 2024 — Receivables - Net jumped 113.51% — and 2025, when it jumped 31.2%.
• Year by year, Receivables - Net stood at $46.1 million in 2023, then soared by 113.51% to $98.5 million in 2024, then jumped by 31.2% to $129.2 million in 2025.
• According to Business Quant data, Receivables - Net over the past three periods registered $129.2 million, $98.5 million, and $46.1 million for Q4 2025, Q4 2024, and Q4 2023 respectively.